MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update MetaVia (Nasdaq: MTVA) reported year-end 2025 results and a corporate update highlighting positive clinical progress and a tightened cash runway. DA-1726 48 mg Phase 1 showed ~9.1% weight loss, improved glucose control and reduced liver stiffness. IRB approval received for Part 3 titration study; dosing expected April 2026 with data in Q4 2026. Vanoglipel Phase 2a showed clinically meaningful metabolic and liver improvements. Cash and equivalents were $10.3M at year-end; January 2026 gross offering proceeds of ~$9.3M are expected to fund operations into Q4 2026.

#MTVA MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MTVA/meta-via-repor...

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 MetaVia (Nasdaq: MTVA) announced expanded global patent protection for vanoglipel (DA-1241), reporting 48 granted and pending patents across the U.S., Europe, Japan, China and other countries. The portfolio, exclusively licensed from Dong-A ST, covers the compound, manufacturing methods and therapeutic uses and provides protection into 2035, unless extended.The patents target treatment applications for metabolic and liver diseases, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and diabetes, and support MetaVia's strategy to maximize long-term value for vanoglipel.

#MTVA MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

www.stocktitan.net/news/MTVA/meta-via-expan...

A közmédia arra kíváncsi, mikor és mennyien nézik az M1, M2, M4, M5, a Duna és Duna World/ M4 Sport csatornákat. 👉 atlatszo.hu/kozpenz/2026...
#közbeszerzés #közmédia #MTVA #nézettség

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum MetaVia (Nasdaq: MTVA) announced that CEO Hyung Heon Kim will speak at the Life Sciences Virtual Investor Forum on March 12, 2026 at 10:30 am ET, discussing the company's pipeline of novel obesity and metabolic therapies.The session is a live, interactive webcast with archived access available; one-on-one investor meetings and pre-registration are offered.

#MTVA MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

www.stocktitan.net/news/MTVA/meta-via-to-hi...

#MTVA: Positive Results for 48 mg Cohort in Phase 1b Trial of DA-1726… buff.ly/fQL0qDk

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering August 2024 Purdue/CME Ag Economy Barometer fell 13 points to 100, matching levels from fall 2015–winter 2016.The Index of Current Conditions declined 17 points to 83, and the Index of Future Expectations dropped 11 points to 108. The Farm Financial Performance Index fell 9 points month-over-month and 14 points year-over-year to its lowest level since July 2020. The Farm Capital Investment Index hit an all-time low of 31. Concern over lower commodity prices rose to 30% of respondents, while 70% expect farmland cash rental rates for the 2025 crop year to remain stable.

#MTVA MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

www.stocktitan.net/news/MTVA/meta-via-annou...

Just In: ( NASDAQ: #MTVA ) MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

BREAKING NEWS: ( NASDAQ: #MTVA ) MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

#MTVA: New Date for Vanoglipel (DA-1241) Presented at AASLD buff.ly/VxULUtR

MetaVia Inc. Announces 1-for-11 Reverse Stock Split MetaVia (Nasdaq: MTVA) announced a 1-for-11 reverse stock split of its common stock, effective 5:00 p.m. ET on December 4, 2025, with trading on a split-adjusted basis beginning December 5, 2025.The reverse split was authorized by stockholders June 30, 2025, and approved by the board at a 1-for-11 ratio to help the company comply with Nasdaq continued listing requirements. Outstanding shares will fall from approximately 25.4 million to 2.3 million, while the number of authorized shares remains 100 million. Conversion and exercise prices for restricted stock units, options and warrants will increase proportionally.Any fractional shares will be rounded down and paid in cash based on the closing Nasdaq price on the last trading day before the split. The stock will continue to trade under the symbol MTVA and a new CUSIP will be 64132R503.

#MTVA MetaVia Inc. Announces 1-for-11 Reverse Stock Split

www.stocktitan.net/news/MTVA/meta-via-inc-a...

Magyar Péter egyenválaszt adott az egyenkérdésekre A Tisza Párt elnöke figyelmeztette az állami médiát. The post Magyar Péter egyenválaszt adott az egyenkérdésekre first appeared on 24.hu.

#MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025… buff.ly/AfB8NVp

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025 MetaVia (Nasdaq: MTVA) presented positive Phase 2a data for oral GPR119 agonist vanoglipel (DA-1241) in presumed MASH at AASLD 2025.In a 16-week randomized, placebo-controlled trial of 109 patients, vanoglipel produced mean HbA1c reductions of –0.54%p (monotherapy) and –0.66%p (100 mg + DPP4i) at Week 16; early HbA1c drops were seen by Week 4. Treatment improved liver inflammation, steatosis (CAP), and liver stiffness (VCTE), lowered biomarkers of cell death, inflammation and fibrosis (CK18F/M30, hs-CRP, CCL2, TIMP1), and reduced pathogenic plasma lipids (glycerolipids DG36:4, TG52:4; glycerophospholipids PE38:4, PE38:5). Vanoglipel was well tolerated with no treatment-emergent discontinuations attributed to drug.

#MTVA MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

www.stocktitan.net/news/MTVA/meta-via-prese...

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update Dosed the First Patient in the 8- Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected by Year-End 2025. $14.3 Million in Cash at End of Third Quarter is E xpected to Fund the Company Into 2026. CAMBRIDGE, Mass., Nov. 6, 2025/ PRNewswire/-- MetaVia Inc., a...

#MTVA MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MTVA/meta-via-repor...

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting CAMBRIDGE, Mass., Oct. 27, 2025/ PRNewswire/-- MetaVia Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data on Vanoglipel, a novel G-Protein-Coupled Receptor 119 agonist, has been accepted for a poster presentation at the American Association for the Study of Liver...

#MTVA MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

www.stocktitan.net/news/MTVA/meta-via-annou...

Ahhoz képest, hogy 500 millió forintot költenek sminkesre és fodrászra, ez egészen szerény összeg.
👉 atlatszo.hu/kozpenz/2025...
Nélkülünk nem tudnál a magánrepülőgépekről 👉 atlatszo.hu/tamogatom
#fizetettközönség #híradó #közbeszerzés #közmédia #közpénz #MTVA

A közmédia 80,3 milliárdot kapott a költségvetésből az első fél évben, 9 milliárddal többet, mint tavaly 14 milliárdot költöttek a bérekre. The post A közmédia 80,3 milliárdot kapott a költségvetésből az első fél évben, 9 milliárddal többet, mint tavaly first appeared on 24.hu.

#MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025… buff.ly/OTCGp14

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update MetaVia (NASDAQ: MTVA) reported Q2 2025 financial results and provided updates on its cardiometabolic drug pipeline. The company dosed the first patient in an extended 8-week 48mg MAD cohort for DA-1726, their obesity treatment candidate. Previous 32mg dose cohort showed promising results with 4.3% average weight loss (max 6.3%) by Day 26.The company also announced an AI-driven collaboration with Syntekabio to explore additional indications for DA-1241, their MASH treatment candidate. New preclinical data showed synergistic benefits when combining DA-1241 with Efruxifermin in reducing liver fat, inflammation, and fibrosis.Financial highlights include $17.6 million cash position expected to fund operations into 2026, reduced R&D expenses to $2.3 million (down from $8.1 million YoY), and a net loss of $4.0 million ($0.26 per share) for Q2 2025.

#MTVA MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MTVA/meta-via-repor...

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 MetaVia (Nasdaq: MTVA) has announced a strategic research collaboration with Syntekabio to expand therapeutic applications of DA-1241, their oral GPR119 agonist. The partnership will utilize Syntekabio's DeepMatcher® AI platform to screen DA-1241 against over 1,700 protein targets for new indications.The collaboration follows positive Phase 2a results from a 16-week study involving 109 subjects, which demonstrated favorable safety and tolerability profiles, along with hepatoprotective and glucose-regulating effects in MASH patients. Initial insights from this AI-driven collaboration are expected later in 2025.

#MTVA MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

www.stocktitan.net/news/MTVA/meta-via-annou...

#MetaVia (Nasdaq: #MTVA) has hit a key milestone as it begins dosing in the 48 mg cohort of its Phase 1 obesity trial for DA-1726. Early results showed strong weight loss and metabolic benefits—without titration. Top-line data is expected in Q4.
#MetaVia
prismmarketview.com/metavia-adva...

Tovább folyik a közpénz a kormányközeli vállalkozó cégéhez, a Visual Europe Production Kft.-hez is, amely verseny nélkül nyert az MTVA tenderén.
👉 atlatszo.hu/kozpenz/2025...
Segíts, hogy az Átlátszó mindenkié maradjon! 👉 atlatszo.hu/tamogatom
#BalásyGyula #közbeszerzés #közmédia #MTVA

Rendkívül szoros együttműködést ígért több szerződésben a magyar közmédia kínai partnereinek. A szerződéseket az Átlátszó peres úton szerezte meg, most további jogi lépéseket tervezünk.
👉 atlatszo.hu/kozadat/2025...
#adatigénylésesper #Kína #MTVA

Missed MetaVia #MTVA at the OTC Markets Virtual Investor Conference? CEO HH Kim joined Senior Analyst David Bautz to discuss the company’s strategy, clinical progress, and what investors should watch.

View the replay: buff.ly/hUUUBMK

#BiotechNews #SmallCap #StockNews

#MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model… buff.ly/AotznvR

A digital illustration showing a healthcare professional holding a tablet with a glowing holographic liver surrounded by medical icons, representing liver health innovation by MetaVia Inc.

#MTVA unveils new data showing its liver drug DA-1241 works even better in combo with Efruxifermin—offering new hope for treating MASH. Details coming from #ADA2025.
#MetaVia
prismmarketview.com/metavia-high...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session MetaVia (MTVA) presented pre-clinical data showing that their GPR119 agonist DA-1241, when combined with Efruxifermin (EFX), demonstrates enhanced hepatoprotective effects in MASH treatment. The 12-week study in mice showed the combination therapy achieved significant improvements: 94% of mice achieved ≥2-point improvement in NAFLD activity score, with marked reductions in inflammatory markers (TNFα -58%, CXCL10 -56%, CCL2 -77%, galectin-3 -87%) and fibrotic markers (type 1 collagen α1 -72%, α-SMA -59%, TIMP1 -88%). While EFX alone reduced body weight by 17%, DA-1241 was weight-neutral, and the combination therapy showed additive benefits independent of weight loss. The data supports DA-1241's potential as part of a combination strategy for treating MASH.

#MTVA MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

www.stocktitan.net/news/MTVA/meta-via-prese...

Aranyosi Péter: Elég nagy bajban lehet a világ, ha már a humoristákat vegzálják A humorista szerint hatalmas öngól volt elvenni tőle a Karinthy-gyűrűt. The post Aranyosi Péter: Elég nagy bajban lehet a világ, ha már a humoristákat vegzálják first appeared on 24.hu.

Az OBSERVER Kft.-nek telefonos, online és személyes megkérdezésen alapuló kutatást is kell végeznie arról, mi a véleménye a közmédiáról a nézőknek. 👉 atlatszo.hu/kozpenz/2025...
🇭🇺 Védd a haza szuverenitását, támogasd az Átlátszót magyar forinttal!👉 atlatszo.hu/tamogatom
#közbeszerzés #közmédia #MTVA